(S)-Pramipexole

CAS: 104632-26-0

Ref. TR-P700750

Produktinformation

• Name: (S)-Pramipexole
• Synonyme: (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine, (6S)-4,5,6,7-Tetrahydro-N⁶-propyl-2,6-benzothiazolediamine, (6S)-6-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, (6S)-N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole, (S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole, (S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole, 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)-, 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-, 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N⁶-propyl-, (6S)-, 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N⁶-propyl-, (S)-, 6-Propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, Mirapexin, Oprymea, Pramipexol, Pramipexol [Spanish], Pramipexole Teva, Pramipexole [USAN:INN], Pramipexolum, Pramipexolum [Latin], Sifrol, Snd 919, Sud 919Cl2Y, Sud919Cl2Y, U-98528E, Unii-83619Peu5T

Beschreibung

Applications (S)-Pramipexole enantiomer. A dopamine-D2-receptor agonist. Antiparkinsonian. Pramipexole (Mirapex, Mirapexin, Sifrol) is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS).[1] It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants.
References Mierau, J., et al.: J. Med. Chem., 30, 494 (1987), Schilling, J.C., et al.: Clin. Pharmacol. Ther., 51, 541 (1992), Kieburtz, K., et al.: J. Am. Med. Assoc., 278, 125 (1997)

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 211.33
• Formel: C₁₀H₁₇N₃S
• Farbe/Form: Neat
• InChl: InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
• InChI Key: InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N
• SMILES: CCCN[C@H]1CCc2nc(N)sc2C1